The way we understand and treat obesity is changing dramatically, driven by scientific advancements. For decades, discussions around weight management focused mainly on lifestyle measures such as dietary
restrictions, exercise, and behavioural counselling. While these remain important, obesity is now increasingly recognised as a chronic, multifactorial disease influenced by biology, genetics, environment, and lifestyle.
“Our understanding of obesity has evolved significantly. It is no longer viewed simply as a matter of diet or willpower, but as a complex medical condition involving multiple biological and environmental factors,” says Dr Ameya Joshi, MD (General Medicine), DM (Endocrinology), Consultant In Charge, Endocrinology, Bhaktivedanta Hospital and Research Institute, Mumbai, and Director, Endocrine and Diabetes Clinic, Borivali West.
This shift is important because it reframes the goal of treatment. The focus is no longer just on “looking thinner,” but on improving metabolic health, preventing serious complications, and enhancing quality of life. Newer therapies such as glucagon-like peptide-1 (GLP-1) are key components of a comprehensive, evidence-based approach to managing obesity as a chronic disease. This shift makes it essential that treatment decisions are grounded in scientific evidence and undertaken under proper medical guidance.
GLP-1 therapies have entered pop culture from celebrity conversations to social media debates creating both curiosity and confusion. While this visibility has increased awareness, it has also revived long-standing biases around body weight and appearance. Obesity treatment is still frequently framed as a cosmetic or “quick fix” solution. In reality, it is a medical intervention aimed at reducing long-term disease risk.
“Unfortunately, many people still perceive obesity treatment as something cosmetic,” explains Dr. Joshi. “But the real objective is to reduce the risk of serious metabolic diseases and improve long-term health outcomes.”
Why Risks Often Go Unnoticed in India
In India, obesity and metabolic risks are often harder to identify early because they are frequently normalised. Social and cultural habits can make overconsumption easy to overlook. Festive eating, large portions, frequent snacking, sedentary routines, poor sleep, and chronic stress can gradually become part of everyday life, making them less likely to be recognised as risk factors. By the time complications appear, the disease burden may already be significant.
There is another important concern in Indian populations: a person may appear to have a “normal weight” while still carrying considerable cardiometabolic risk.
“In Indian populations, metabolic risk can exist even in individuals who appear to have a normal body weight. This is why visual appearance should never be mistaken for clinical safety,” notes Dr. Joshi.
India’s rising burden of obesity, diabetes, and cardiovascular disease highlights why obesity must be treated as a serious health concern rather than a cosmetic issue.
Obesity: A Chronic, Multifactorial Disease
One of the most important messages modern medicine is trying to communicate is that obesity is not merely a lifestyle issue; it is a chronic, relapsing disease that affects multiple organs and systems in the body. Similar to conditions such as hypertension or diabetes, obesity requires long-term management and medical attention.
It develops through a complex interaction of factors, including genetics, hormonal regulation, diet quality, physical inactivity, sleep patterns, stress, and the environment in which people live.
The modern environment, often referred to as an “obesogenic environment,” provides widespread access to calorie-dense foods while reducing opportunities for physical activity. Over time, these conditions influence the body’s metabolism and appetite regulation.
“Obesity develops through a combination of biological, environmental, and behavioural influences. Treating it effectively requires addressing all these factors together,” says Dr. Joshi.
In India, early recognition and management of obesity could significantly reduce the burden of non-communicable diseases. Untreated obesity increases the risk of conditions such as type 2 diabetes, cardiovascular disease, obstructive sleep apnea, osteoarthritis, fatty liver disease, and depression.
The body also actively defends its weight through biological mechanisms. As weight increases, hormonal and metabolic changes can increase hunger, reduce satiety, and make weight regain more likely often described as the body’s weight-set-point mechanism.
“This biological response explains why maintaining weight loss can be difficult. The body tends to defend its weight, which is why medical support and long-term strategies are often necessary,” explains Dr. Joshi.
This is why modern obesity care increasingly focuses on comprehensive management that combines lifestyle changes, behavioural support, and when appropriate, medical therapies such as GLP-1-based treatments.
GLP-1 Therapy Simplified
To understand the growing interest in GLP-1 therapies, it is helpful to look at how the body naturally regulates appetite and metabolism.
After eating, the gut releases hormones that communicate with the brain, pancreas, and other organs to regulate fullness, blood sugar levels, and energy balance. One of the key hormones involved in this process is glucagon-like peptide-1 (GLP-1).
GLP-1 therapies work by mimicking this natural hormone. They slow digestion, help patients feel full earlier, reduce appetite, and improve blood sugar control.
“GLP-1 therapies work by supporting the body’s natural appetite-regulation pathways. They help reduce hunger, increase satiety, and improve glucose control, which makes them valuable tools in managing obesity,” explains Dr. Joshi.
This biological mechanism is what differentiates GLP-1 therapies from traditional weight-management approaches that rely solely on behavioural changes.
However, it is important to emphasise that GLP-1 therapies are not a standalone solution.
“These medications are most effective when used as part of a broader treatment plan that includes nutrition, physical activity, behavioural support, and regular medical follow-up,” Dr. Joshi adds.
Emerging research also suggests that certain GLP-1-based therapies may offer additional benefits beyond weight loss, including improvements in cardiovascular and metabolic outcomes.
The Impact of GLP-1 Therapy on Weight Loss
GLP-1 therapy represents a major shift in obesity treatment because it targets the underlying biology of the disease, not just behaviour.
For many eligible patients, these therapies can support meaningful weight reduction when combined with dietary changes, physical activity, and long-term clinical monitoring.
Studies have shown clinically significant weight reduction, although results vary depending on the specific treatment and individual patient factors.
“The most meaningful outcomes are improvements in metabolic health, such as better blood sugar control, lower blood pressure, improved mobility, and better sleep,” Dr. Joshi says. “These therapies are about improving health, not achieving a certain body image.”
For individuals living with obesity, effective care should offer dignity, clarity, and support—not judgement.
GLP-1 therapies represent meaningful scientific progress, but their true value lies in responsible and ethical use alongside lifestyle interventions and behavioural support.
The future of obesity management lies in combining scientific innovation with compassionate, patient-centred care. Building a healthier society begins with informed choices, equitable access to treatment, and conversations that prioritise health over appearance.
“Obesity care must shift away from stigma and toward science-based treatment and empathy. When we focus on health rather than appearance, we create better outcomes for patients,” concludes Dr. Joshi.
